[
  {
    "chunk_id": 0,
    "text": "Original Investigation Dipping Status, Ambulatory Blood Hypertension Control, Cardiovascular Disease, and Kidney Disease Progression: A Multicenter Cohort Study of chronic kidney disease Silvio Borrelli, Carlo Garofalo, Francis B. Gabbai, Paolo Chiodini, Simona Signoriello, Ernesto Paoletti, MauraRavera, ElisabettaBussalino, VincenzoBellizzi, MariaElenaLiberti, LucaDeNicola, andRobertoMinutolo VisualAbstractonline Rationale Objective: Ambulatory Blood Results: The mean patient age was 63. 8 years, Hypertension (blood pressure) monitoring allows concurrent 61%weremale, and26. 4%haddiabetes; estimated glomerular filtration rate Completeauthorandarticle evaluation of blood pressure control and nocturnal blood pressure dipwas 41. 1 ± 20. 8 milliliters per minute/1. 73 m2. The dipping informationprovidedbefore ping status, both related to adverse outcomes. prevalence in each of the 4 groups was as folreferences. However, few studies have assessed the proglows: nocturnal dipping with ambulatory blood pressure at Correspondenceto nostic role of combining information on dipping goal, 18. 6%; no nocturnal dipping with ambulaR. Minutolo(roberto. status and achieved ambulatory blood pressure in patients tory blood pressure at goal, 20. 5%; nocturnal dipping with minutolounicampania. it) with chronickidneydisease (chronic kidney disease). ambulatory blood pressure above goal, 11. 8%; and no S. B. andC. G. contributed nocturnaldippingwithambulatoryBPabovegoal, equallytothiswork. Study Design: Prospective observational cohort 49. 1%. Among patients with ambulatory blood pressure AmJKidneyDis. study. abovegoal, theriskofcardiovasculareventswas 81(1): 15-24. Published Setting Participants: 906 patients with greaterintheabsence(heart rate, 2. 7995%CI, 1. 64onlineJune13, 2022. hypertension and chronic kidney disease attending 1 of 3 Italian 4. 75) and presence (heart rate, 2. 05 95% CI, 1. 10doi: 10. 1053/ nephrologyclinics. 3. 84) of nocturnal dipping. The same held true j. ajkd. 2022. 04. 010 for risk of Kidney disease progression (HRs of 2022TheAuthors. Exposure: Four groups were defined by simulta2. 40 95% CI, 1. 58-3. 65 and 2. 11 95% CI, PublishedbyElsevierInc. neously classifying systolic ambulatory blood pressure levels 1. 28-3. 48 in the absence and presence of onbehalfoftheNational as being at goal (daytime SBP 135 and nightnocturnal dipping, respectively). Patients at the KidneyFoundation, Inc. This time SBP 120 mm Hg) or above goal, and the ambulatory blood pressure goal but who did not experience isanopenaccessarticle presence or absence of nocturnal dipping (nightnocturnal dipping had an increased risk of the undertheCCBY-NC-ND timetodaytimeSBPratioof0. 9versus≥0. 9). cardiovascular end point (heart rate, 2. 06 95% CI, license(http: // creativecommons. org/ Outcome: The composite of time to initiation of 1. 15-3. 68) and the Kidney disease progression licenses/by-nc-nd/4. 0/). maintenancedialysisorestimatedglomerularfiltraoutcome (heart rate, 1. 8295%CI, 1. 17-2. 82). tionrate(estimated glomerular filtration rate)decline≥50%, andthecomposite Limitations: Lack of a diverse cohort (all those offatalandnonfatalcardiovascularevents. enrolled were White). Residual uncontrolled confounding. Analytical Approach: Multivariable Cox proportionalhazardsmodelswereusedtoestimaterisks Conclusions: SystolicambulatoryBPabovegoal ofkidneydiseaseprogressionandcardiovascular or the absence of nocturnal dipping, regardless disease in the 4 exposure groups where ofambulatoryBP, is associatedwithhigherrisks nocturnal dipping with systolic ambulatory blood pressure at of cardiovascular disease and Kidney disease goalwasthereference group. progressionamong patientswithCKD. Ambulatory Blood Hypertension (blood pressure) monitoring is widely evaluating the prognosis of chronic kidney disease patients based on recognized as the gold standard to estimate true ambulatory blood pressure monitoring have focused on the role of hypertensive status by identifying blood pressure phenotypes derived nocturnal nondipping status and above-goal ambulatory from the potential mismatch between ambulatory and blood pressure independent of each other even though these 2 conditions are frequently associated. Indeed, current guidelines justify intensifying blood pressure management in patients with Editorial, p. 10 above-goal ambulatory blood pressure independent of the patients nocturnal dipping status. Conversely, very little is known office blood pressure measures. In addition, ambulatory blood pressure is the regarding the management of patients with nondipping only tool for assessing abnormal circadian blood pressure patterns status and ambulatory blood pressure at goal.",
    "word_count": 589,
    "char_count": 4713,
    "sentence_count": 66,
    "metadata": {
      "source_file": "1-s2.0-S0272638622007090-main.pdf",
      "extraction_date": "2025-12-31T14:19:31.422573",
      "document_type": "medical_guideline",
      "language": "en",
      "keywords": [
        "chronic kidney disease",
        "CKD",
        "dialysis",
        "nephrology"
      ],
      "chunk_index": 0,
      "total_chunks": 12,
      "position": "1/12",
      "content_type": "evidence",
      "content_type_confidence": 4,
      "medical_entities": [
        "chronic kidney disease",
        "glomerular filtration rate",
        "cardiovascular disease",
        "blood pressure control",
        "monitoring"
      ],
      "entity_count": 5
    }
  },
  {
    "chunk_id": 1,
    "text": "The decision as to such as the absence of physiological blood pressure decline during whether such patients need to be treated requires as a first sleep. 1-3 stepmoreknowledgeoftheglobalriskassociatedwiththis In patients with chronic Kidney disease (chronic kidney disease), phenotype. ambulatory blood pressure predicts cardiovascular (CV) and Kidney Unfortunately, it remains unclear whether the presence disease outcomes better than does office blood pressure. 4-9 Similarly, of isolated nondipping status (ie, with ambulatory blood pressure at nondippingstatusisassociatedwithapoorCVandkidney goal) is associated with a different CV risk than that prognosis in chronic kidney disease patients. 4-6 Nonetheless, studies observed in chronic kidney disease patients with ambulatory blood pressure above goal AJKD Vol81Iss1January2023 15 Borrelli et al changes in antihypertensive therapy 2 weeks before ambuPLAIN-LANGUAGE SUMMARY latory blood pressure monitoring, atrial fibrillation, or inadequate Among patients with chronic Kidney disease (chronic kidney disease), ambulatoryBPmonitoring(daytimeandnighttimesystolic/ ambulatory Blood Hypertension (blood pressure) monitoring improves diastolic recordings 20 and 7, respectively14). The instithe identification of individuals at High risk of clinical tutionalreviewboardsoftheparticipatingcentersapproved disease outcomes. Those with uncontrolled ambulatory theprotocol, andallpatientssignedinformedconsent. blood pressure are known to have a higher risk of developing Medical history, demographics, laboratory data, and cardiovascular disease and Kidney disease progression, current therapy were collected at baseline. If it was not available from the baseline visit, 24-hour Urine collection particularlywhentheirambulatoryBPdoesnotdeclineby was requested to measure Protein and Sodium excretion. atleast10%atnight. Whetherthisisalsotrueforpatients Collectionwasconsideredinaccurateandwasrepeatedifthe with presence of optimal ambulatory blood pressure levels but a blood pressure value of the measured Creatinine excretion ratewas outside patternofnonighttimedeclineislargelyunknown. We the60%to140%rangeofthevalue. 8TheeGFRwascalcumeasuredambulatoryBPin900ItalianpatientswithCKD latedbythe2009CKD-EPIcreatinineequation; becausethe andfollowedthemforseveralyears. Wefoundthat, inCreatinine was not standardized to isotope-dilution mass dependentofambulatoryBPlevel, theabsenceofnightspectrometryvalues, wereducedcreatininelevelsby5%. 15 timereductionsinBPwasassociatedwithworseningof Standardized office blood pressure measurement was obtained chronic kidney disease and more frequent cardiovascular events. The during aclinic visit(8: 00-11: 00 AM), in asitting position, absenceofnighttimedeclinesinBPisanindependentrisk 3 times at 5-minute intervals by the same physician, who factor for adverse events among patients with chronic kidney disease. was masked to the results of ambulatory blood pressure recordings to Futurestudiesareneededtoexaminewhethertreatingthe avoid any influence on the office readings. The office blood pressure values were determined as the mean of the 6 values absence of nighttime declines in blood pressure improves clinical recorded on the 2 consecutive days in which the ambuoutcomes. latory blood pressure monitoring device was installed and removed. Antihypertensive medications were administered from andanondippingpattern. Similarly, theprognosticroleof 8: 00AM-10: 00PM toachieveanofficeBPof130/80 mm isolated nondipping status on Kidney outcome has been Hg (this goal was used during the whole study period). investigatedonlyrarelyandwaslimitedtoCKDpatientsin AmbulatoryBPwasmonitoredusingaSpacelabs90207 Japan. 10, 11 We previously demonstrated that switching devicewithcuffsizechosenaccordingtothepatientsarm administration of 1 antihypertensive drug from morning circumference and fixed to the nondominant arm. Three toeveninginCKDpatientswithnondippingstatusand24blood pressure readings were taken in the morning (8: 00-11: 00 AM) hour ambulatory blood pressure at target is effective in restoring concomitant with measurements with an aneroid sphygphysiologic nocturnal blood pressure decline. 12 This finding was not momanometertoensureadifferenceoflessthan5mmHg confirmed in Black individuals with hypertensive chronic kidney disease. 13 between the 2 sets of values. The monitor recorded blood pressure However, no information on outcomes were provided in every15minutesbetween7: 00AMand11: 00PMandevery either study. 30 minutes between 11: 00 PM and 7: 00 AM. Therefore, we designed a prospective observational Daytime and nighttime periods were derived from the study toassess the prognosticeffect ofsystolic ambulatory diaries recorded by the patients during the ambulatory blood pressure blood pressure goal and dipping status, alone or in combination, on monitoring, which was always performed on a workday fatalandnonfatalCVeventsandkidneydiseaseprogression and while the patient was receiving the prescribed antiin a large cohort of patients with chronic kidney disease who were not hypertensive therapy. Patients had no access to the receiving Dialysis. ambulatory blood pressure values.",
    "word_count": 595,
    "char_count": 5198,
    "sentence_count": 31,
    "metadata": {
      "source_file": "1-s2.0-S0272638622007090-main.pdf",
      "extraction_date": "2025-12-31T14:19:31.422573",
      "document_type": "medical_guideline",
      "language": "en",
      "keywords": [
        "chronic kidney disease",
        "CKD",
        "dialysis",
        "nephrology"
      ],
      "chunk_index": 1,
      "total_chunks": 12,
      "position": "2/12",
      "content_type": "treatment",
      "content_type_confidence": 6,
      "medical_entities": [
        "chronic kidney disease",
        "creatinine",
        "sodium",
        "antihypertensive",
        "dialysis",
        "cardiovascular disease",
        "monitoring"
      ],
      "entity_count": 7
    }
  },
  {
    "chunk_id": 2,
    "text": "Patients had no access to the receiving Dialysis. ambulatory blood pressure values. Exposure Factors Methods To explore the isolated prognostic effect of achieving the Study Design and Measurements targetsystolicambulatoryBP(daytimesystolicBPof135 In this multicenter, prospective cohort study, consecutive mm Hg and nighttime systolic blood pressure of 120 mm Hg) and patientswererecruitedin3nephrologyoutpatientclinicsin dipping status (nighttime to daytime systolic blood pressure ratio 2005-2015. Inclusion criteria were chronic kidney disease stages 2-5 (not of 0. 9), we classified patients in 4 mutually exclusive receiving Kidney replacement therapy Dialysis or transcategories: nocturnal dipping with ambulatory blood pressure at goal, plant), hypertension (either office blood pressure ≥140/90 mm Hg nocturnal nondipping with ambulatory blood pressure goal, nocturnal without antihypertensive treatment or receiving blood pressure drugs dipping with ambulatory blood pressure above goal, and nocturnal withanyBPvalues), andnephrologycarelasting≥6months nondipping with ambulatory blood pressure above goal. with at least 2 visits in the nephrology clinic before enrollment. The exclusion criteria included a recent episode of Outcomes acute Kidney injury (defined as estimated glomerular filtraCo-primary outcomes were the occurrence of fatal and tion rate estimated glomerular filtration rate change 30% in the previous 3 months), nonfatal CV events and a composite Kidney disease 16 AJKD Vol81Iss1January2023 Borrelli et al progressionoutcome. CVeventsincludeddeathsduetoCV Two sensitivity analyses were done. First, we included causescertifiedbytheNationalDeathRegistryandnonfatal ambulatory blood pressure at goal and dipping status separately or events requiring hospitalizations due to myocardial insimultaneouslyinthemultivariableCoxmodelsinorderto farction, congestive Heart failure, stroke, revascularization further investigate the isolated effect of ambulatory blood pressure at procedures, peripheral vascular disease, and nontraumatic goal and dipping status on outcomes. Second, we estiamputation. For the CV survival analysis, follow-up was mated the Kidney disease progression risk associated with computed from the initial visit to December 2019 or the these2variablesbyusingonlydialysisinitiationasanend dateofCVevent, non-CVdeath, orfirstdialysistreatment. point. The Kidney disease progression outcome was a composite Data were analyzed by using STATA 11. 2 (StataCorp). of ≥50% estimated glomerular filtration rate decline or initiation of maintenance dialysis. Patients were followed until December 2019 or until Results the date of the Kidney disease progression outcome or death, whichever occurred first. Cohort Characteristics We included 906 out of 1, 116 eligible hypertensive patients. Reasons for exclusion were inadequate ambulatory Statistical Analysis BPrecordings(n65), recentchangesinantihypertensive Continuous variables are expressed as mean and SD or as therapy(n 49), atrial fibrillation (n 21), eGFRchange median and IQR (according to their distribution) and 30% (n 11), loss to follow-up after baseline visit (n categorical variables were expressed as percentage. Dif26), and refusal to participate (n 38). ferences between groups were tested by means of 1-way Overall, nondipping status was detected in 70% of paanalysis of variance (ANOVA) or Kruskal-Wallis for tients, andsystolicambulatoryBPwasabovegoalin61%of continuous variables (according to their distribution) and thecohort(43%fordaytimeand57%fornighttimevalues). χ2testforcategoricalvariables. Themedianfollow-upwas AfterstratifyingbydippingstatusandambulatoryBPgoal, estimated by the inverse Kaplan-Meier approach. 16 167patients(18%)haddippingstatuswithambulatoryBP The incidence rate was determined by dividing the atgoal, 187(21%)hadnondippingstatusandambulatory number of events by the total number of person-years BPatgoal, 103(11%)haddippingstatusandambulatoryBP accumulated with 95% CI calculated assuming Poisson abovegoal, andtheremaining449(50%)hadnondipping distribution. Because Dialysis and non-CV death before statusandambulatoryBPabovegoal. Dialysis are competing events for CV outcomes, we The baseline demographic and clinical characteristics calculated the cumulative incidence of fatal and nonfatal of these 4 groups are presented in Table 1. All patients CVeventsbyusingthecompetingriskapproachdescribed were White; those with nocturnal nondipping status by Fine and Gray. 17 A similar methodology was used for with ambulatory blood pressure above goal were older, predomiincidence of the Kidney disease progression outcome by nantlymale, andhadahigherprevalenceofdiabetesand considering all-cause death as competitive event. Cumuprior CV disease. They also had more advanced Kidney lative incidence curves were compared using Gray test.",
    "word_count": 584,
    "char_count": 4870,
    "sentence_count": 29,
    "metadata": {
      "source_file": "1-s2.0-S0272638622007090-main.pdf",
      "extraction_date": "2025-12-31T14:19:31.422573",
      "document_type": "medical_guideline",
      "language": "en",
      "keywords": [
        "chronic kidney disease",
        "CKD",
        "dialysis",
        "nephrology"
      ],
      "chunk_index": 2,
      "total_chunks": 12,
      "position": "3/12",
      "content_type": "evidence",
      "content_type_confidence": 4,
      "medical_entities": [
        "chronic kidney disease",
        "acute kidney injury",
        "glomerular filtration rate",
        "antihypertensive",
        "dialysis",
        "heart failure"
      ],
      "entity_count": 6
    }
  },
  {
    "chunk_id": 3,
    "text": "Cumuprior CV disease. They also had more advanced Kidney lative incidence curves were compared using Gray test. 18 disease as evidenced by lower estimated glomerular filtration rate and higher proMultivariable Cox proportional hazards models were teinuria. Patients with only 1 abnormal parameter (ie, usedtoestimatetherisk(hazardratioheart rateand95%CI)of either nondipping status or ambulatory blood pressure above goal) the CV end point and the Kidney disease progression had a risk profile intermediate between the reference outcome in the 4 groups based on dipping status and group (nocturnal dipping and ambulatory blood pressure at goal) ambulatory blood pressure goal (considering nocturnal dipping status and patients with nondipping status and ambulatory and ambulatory blood pressure at goal as the reference group). In the blood pressure above goal. Cause of Kidney disease did not differ Cox models for the Kidney disease progression outcome, across the 4 groups (hypertensive nephropathy, 33%; death before that outcome was treated as censoring event; diabetic Kidney disease, 22%; glomerulonephritis, 18%; intheCoxmodelsfortheCVendpoint, thekidneydisease autosomal polycystic Kidney disease, 5%; and other/ progression outcome and non-CV death were treated as unknown, 22% P 0. 2). censoring events. blood pressure values and treatment in the 4 groups are depicted Allsurvivalmodelswerestratifiedbycentertotakeinto in Table 2. No difference was found in number of account potential differences in the baseline risk of the antihypertensive drugs across groups. However, those Kidney disease progression outcome and the CV end point with nondipping status and ambulatory blood pressure above goal across the 3 centers. Each model was adjusted for baseline received fewer renal artery stenosis inhibitors (likely due to a reduced covariates identified a priori: age, sex, body mass index, glomerular estimated glomerular filtration rate) and more calcium channel Diabetes, prior CV disease, smoking, left ventricular hyblockers, central α-agonists, and adrenergic blockers. pertrophy (LVH) diagnosed by echocardiography, office Associated with a higher prevalence of prior CV disease systolic blood pressure, estimated glomerular filtration rate, log-transformed proteinuria, total anddiabetes, prescriptionofantiplateletdrugswasmore cholesterol, serum phosphate, hemoglobin, use of reninfrequent in this group while prescription rate of statins angiotensin system (renal artery stenosis) inhibitors, use of statins, and waslower. Adherencetolow-sodiumdietwaslimitedin number of antihypertensive drugs. all groups. AJKD Vol81Iss1January2023 17 Borrelli et al Table 1. Demographic and Clinical Features of Patients Stratified by Achievement of Systolic Ambulatory blood pressure Goal and Dipping Status Ambulatory BPatGoal Ambulatory BPAboveGoal Dippers Nondippers Dippers Nondippers (n167) (n187) (n103) (n449) P Age, y 58. 7±15. 0 62. 2 ±14. 2 65. 5 ±13. 1 66. 0±13. 4 0. 001 Malesex 47. 9% 57. 8% 68. 9% 65. 5% 0. 001 Diabetes 19. 7% 23. 0% 34. 0% 28. 5% 0. 03 HistoryofCVdisease 22. 8% 25. 7% 33. 0% 31. 6% 0. 09 Smoking 23. 4% 21. 4% 30. 1% 26. 7% 0. 3 LVH 50. 9% 59. 4% 65. 1% 78. 4% 0. 001 body mass index, kg/m2 27. 6 ±4. 4 28. 5 ±5. 4 27. 7±4. 8 27. 7 ±5. 1 0. 3 estimated glomerular filtration rate, milliliters per minute/1. 73m2 49. 9±23. 5 43. 9 ±19. 2 40. 0±22. 4 36. 7±21. 0 0. 001 Cholesterol, milligrams per deciliter 195±42 186±40 186±40 193±50 0. 1 Calcium, milligrams per deciliter 9. 5±0. 6 9. 4±0. 6 9. 4±0. 5 9. 4±0. 6 0. 1 Phosphate, milligrams per deciliter 3. 9±0. 8 3. 8±0. 8 3. 9±0. 8 3. 9±0. 7 0. 7 Hemoglobin, grams per deciliter 13. 1 ±1. 7 12. 9 ±1. 7 12. 6 ±1. 8 12. 3 ±1. 9 0. 001 Proteinuria, g/d 0. 20 0. 08-0. 68 0. 25 0. 09-0. 83 0. 270. 06-1. 00 0. 600. 11-1. 50 0.",
    "word_count": 594,
    "char_count": 3815,
    "sentence_count": 110,
    "metadata": {
      "source_file": "1-s2.0-S0272638622007090-main.pdf",
      "extraction_date": "2025-12-31T14:19:31.422573",
      "document_type": "medical_guideline",
      "language": "en",
      "keywords": [
        "chronic kidney disease",
        "CKD",
        "dialysis",
        "nephrology"
      ],
      "chunk_index": 3,
      "total_chunks": 12,
      "position": "4/12",
      "content_type": "reference",
      "content_type_confidence": 3,
      "medical_entities": [
        "glomerular filtration rate",
        "nephropathy",
        "proteinuria",
        "calcium",
        "phosphate",
        "hemoglobin",
        "antihypertensive",
        "statins"
      ],
      "entity_count": 8
    }
  },
  {
    "chunk_id": 4,
    "text": "20 0. 08-0. 68 0. 25 0. 09-0. 83 0. 270. 06-1. 00 0. 600. 11-1. 50 0. 001 24-Hour urinarysodium excretion, mEq/da 146±61 147±55 153±62 155±66 0. 4 Continuousdatagivenasmean±SDormedianIQR. AmbulatoryBPatgoaldefinedasdaytimeandnighttimeSBPof135and120mmHg, respectively; dipping statusdefinedasratioofnighttimetodaytimeSBPof0. 9). Abbreviations: body mass index, bodymassindex; blood pressure, bloodpressure; CV, cardiovascular; estimated glomerular filtration rate: estimatedglomerular filtrationrate; LVH, leftventricularhypertrophy; SBP, systolicbloodpressure. aAvailablein708patients. Table2. BloodPressureCharacteristicsandTherapeuticFeaturesofPatientsStratifiedbyAchievementofSystolicAmbulatoryBP GoalandDippingStatus Ambulatory BPatGoal Ambulatory BPAboveGoal Dippers Nondippers Dippers Nondippers (n167) (n187) (n103) (n449) P Office SystolicBP, mmHg 140±19 132±17 153±17 149±19 DiastolicBP, mmHg 82 ±11 78±10 83 ±12 83 ±11 24-hour SystolicBP, mmHg 117±8 113±8 140±11 141±14 DiastolicBP, mmHg 71 ±8 68±8 77±11 78±11 Daytime SystolicBP, mmHg 123±8 115±8 147±12 141±15 DiastolicBP, mmHg 75 ±9 71 ±8 82 ±12 79±11 Nighttime SystolicBP, mmHg 105±8 110±7 125±11 140±15 DiastolicBP, mmHg 61 ±7 64±8 67±11 75 ±11 Nighttimetodaytimeratioofsystolic blood pressure 0. 85±0. 04 0. 96±0. 04 0. 85±0. 04 0. 99±0. 07 blood pressure-lowering drugs No. ofdrugs 21-3 21-3 31-3 31-4 0. 6 ACEIand/orARB 84. 4% 80. 8% 76. 7% 63. 9% 0. 001 Diuretic 35. 3% 41. 2% 44. 7% 36. 1% 0. 3 Calciumchannelblockers 38. 9% 41. 7% 45. 6% 54. 6% 0. 001 β-Blockers 34. 8% 32. 1% 37. 9% 34. 1% 0. 8 Centralαagonists 6. 6% 7. 5% 9. 7% 17. 4% 0. 001 Adrenergicblockers 4. 8% 3. 7% 1. 9% 10. 0% 0. 001 Low-Sodium dieta 26. 1% 20. 8% 20. 7% 22. 3% 0. 7 Statins 37. 8% 38. 5% 29. 1% 24. 1% 0. 001 Epoetin 4. 8% 4. 8% 10. 7% 9. 4% 0. 1 Antiplateletsb 23. 6% 26. 0% 24. 5% 40. 8% 0. 001 Continuousdatagivenasmean±SDormedianIQR. Abbreviations: angiotensin-converting enzyme inhibitor, angiotensin-convertingenzymeinhibitors; angiotensin receptor blocker, angiotensinIIreceptorblockers; blood pressure, Blood Hypertension. aAvailablein708patients; lowsodiumdietdefinedasurinarysodiumexcretion≤100mEq/d. bAntiplateletsincludeaspirin, clopidogrel, dipyridamole, andticlopidine. 18 AJKD Vol81Iss1January2023 Borrelli et al Figure 1. Cumulative incidence of composite CV (A) and Kidney disease progression end points (B) by competing risk analysis in chronickidneydiseasepatientsstratifiedin4groupsaccordingtodippingstatus(nighttimetodaytimeratioofSBPof0. 9)andambulatoryBPgoal(daytimeandnighttimeSBP135and120mmHg, respectively). PatientswithnocturnaldippingstatuswithambulatoryBPatgoalaredepictedbythegreydottedline. ThosewithnondippingstatusandambulatoryBPatgoalarethegreysolidline. ThosewithdippingstatuswithambulatoryBPabovegoalaretheblackdottedline. ThosewithnondippingstatuswithambulatoryBP abovegoalaretheblacksolidline. Abbreviation: blood pressure, bloodpressure; CV, cardiovascular; SBP, systolicbloodpressure. Survival Analysis: Cardiovascular Risk experienced an estimated glomerular filtration rate decline of ≥50%, and 180 initiated During a median follow-up period of 7. 8 (IQR, 3. 7-12. 7) maintenance Dialysis. The incidence rate of Kidney disease years we recorded 220 CV events (116 nonfatal) correprogression events in the 4 groups is depicted in sponding to 3. 80 (95% CI, 3. 33-4. 33) events per 100 Figure 1B. The highest adjusted risk of this outcome was patient-years. Competing risk analysis showed progressive observed in patients with ambulatory blood pressure above goal, with greaterincidenceoftheCVendpoint acrossthe4groups, no difference by nocturnal dipping status (P 0. 5). with the highest incidence occurring in patients with Among patients with ambulatory blood pressure at goal, nondipping nocturnalnondippingstatusandambulatoryBPabovegoal status was associated with 82% greater risk of the Kidney (P for trend 0. 001; Fig 1A). After adjustment for podisease progression outcome (Fig 2). tential confounders, the risk for fatal and nonfatal CV TheisolatedeffectofambulatoryBPatgoalanddipping events was 2. 1-fold higher in patients with nocturnal status on the risk of the Kidney disease progression nondipping status and ambulatory blood pressure at goal, compared outcome persisted when ambulatory blood pressure at goal and dipwiththereferencegroupofdippingstatusandambulatory ping status were included separately (HRs of 1. 66 95% blood pressure at goal (Fig 2). Among patients with ambulatory blood pressure CI, 1. 23-2. 23 and 1. 52 95% CI, 1. 15-2. 02, respecabove goal, CV risk was 2. 1and 2. 8-fold higher in tively); in the model including both variables, ambulatory patients with dipping and nondipping status, respectively. blood pressure at goal (heart rate, 1. 52 95% CI, 1. 12-2.",
    "word_count": 596,
    "char_count": 4787,
    "sentence_count": 119,
    "metadata": {
      "source_file": "1-s2.0-S0272638622007090-main.pdf",
      "extraction_date": "2025-12-31T14:19:31.422573",
      "document_type": "medical_guideline",
      "language": "en",
      "keywords": [
        "chronic kidney disease",
        "CKD",
        "dialysis",
        "nephrology"
      ],
      "chunk_index": 4,
      "total_chunks": 12,
      "position": "5/12",
      "content_type": "reference",
      "content_type_confidence": 4,
      "medical_entities": [
        "glomerular filtration rate",
        "sodium",
        "statins",
        "dialysis"
      ],
      "entity_count": 4
    }
  },
  {
    "chunk_id": 5,
    "text": "blood pressure at goal (heart rate, 1. 52 95% CI, 1. 12-2. 07) and dipping The degree to which risk was greater amongpatients with status (heart rate, 1. 39 95% CI, 1. 04-1. 86) remained signifiambulatory blood pressure above goal did not differ based on dipping cantly associated with the Kidney disease progression status (P 0. 2). outcome. TheisolatedeffectofambulatoryBPatgoalanddipping In a sensitivity analysis, we defined the Kidney disease status on the risk of the CV end point persisted when progression outcome as initiation of maintenance Dialysis; ambulatory blood pressure at goal and dipping status were included this outcome was recorded in 290 patients (180 without separately (HRs of 1. 70 95% CI, 1. 20-2. 41 and 1. 73 estimated glomerular filtration rate decline of ≥50% and 110 after detecting estimated glomerular filtration rate 95%CI, 1. 23-2. 42, respectively); inthemodelincluding decline of ≥50%). The adjusted risk of Dialysis initiation both variables, ambulatory blood pressure at goal (heart rate, 1. 53 95% CI, was1. 60(95%CI, 1. 01-2. 54)inpatientswithambulatory 1. 07-2. 19) and dipping status (heart rate, 1. 58 95% CI, 1. 11blood pressure at goal and nondipping status; among patients with 2. 23)remainedsignificantlyassociatedwithCVoutcome. ambulatory blood pressure above goal, the adjusted risk was 1. 72 (95% CI, 1. 02-2. 90) and 2. 19 (95% CI, 1. 42-3. 38) in Survival Analysis: Kidney Disease Progression those with dipping and nondipping status, respectively. Outcome Werecorded315kidneydiseaseprogressioneventsduring Discussion a median follow-up periodof 10. 5 (IQR, 4. 9-13. 4) years, corresponding to a crude event rate of 4. 94 (95% CI, In this prospective study performed in over 900 patients 4. 42-5. 52) per 100 patient-years. Of these patients, 135 with hypertension and chronic kidney disease, 24-hour blood pressure monitoring AJKD Vol81Iss1January2023 19 Borrelli et al Figure 2. Adjusted heart rate for composite CV (A) and Kidney disease progression end points (B) in chronic Kidney disease patients stratified in 4 groups according to dipping status (nighttime to daytime ratio of systolic blood pressure of 0. 9) and ABP goal (daytime and nighttime systolic blood pressure 135 and 120 mm Hg, respectively). Abbreviations: ABP, ambulatory Blood Hypertension; blood pressure, Blood Hypertension; CV, cardiovascular; heart rate, hazardratio. demonstratedthatthecoexistenceofanalteredcircadianBP conditions frequently coexist, in the current study we profile together with systolic ambulatory blood pressure above goal is combined information on dipping status and ambulatory the most frequent pattern (detected in about half of pablood pressure to assess their isolated prognostic effect on CV and tients)andisassociatedwithhighestriskofCVandkidney Kidney disease outcomes. disease outcomes. Of major interest, absence of nocturnal In our cohort, nondipping status was detected in 70% dippingconstitutesasignificantpredictorofCVandkidney of patients, while daytime and/or nighttime systolic blood pressure diseaseoutcomesevenwhenambulatoryBPisatgoal. was above goal (135 and 120 mm Hg, respectively) in Thesefindingsaddnovelinformationontheprognostic 61% of the patients. Stratifying patients by these ambularelevance of ambulatory blood pressure measurement in the chronic kidney disease tory blood pressure characteristics is useful to better define prognosis population. Indeed, it is well recognized that ambulatory in a chronic kidney disease population. Indeed, such an approach allows the blood pressure better predicts CV and Kidney disease risk in chronic kidney disease identification of patients who carry the highest incidence patientsascomparedwithofficeBP. 4-9Similarly, weknow rate of CV and Kidney disease events as being those with that nondipping is highly prevalent in chronic kidney disease cohorts and is nondipping status and ambulatory blood pressure above goal (a more frequently observed in older patients as well as in subgroup constituting half of the cohort). Although the thosewithmoreseverekidneydisease.",
    "word_count": 570,
    "char_count": 4090,
    "sentence_count": 53,
    "metadata": {
      "source_file": "1-s2.0-S0272638622007090-main.pdf",
      "extraction_date": "2025-12-31T14:19:31.422573",
      "document_type": "medical_guideline",
      "language": "en",
      "keywords": [
        "chronic kidney disease",
        "CKD",
        "dialysis",
        "nephrology"
      ],
      "chunk_index": 5,
      "total_chunks": 12,
      "position": "6/12",
      "content_type": "evidence",
      "content_type_confidence": 4,
      "medical_entities": [
        "chronic kidney disease",
        "glomerular filtration rate",
        "dialysis",
        "monitoring"
      ],
      "entity_count": 4
    }
  },
  {
    "chunk_id": 6,
    "text": "Although the thosewithmoreseverekidneydisease. 19ThisabnormalBP coexistence of ambulatory blood pressure above goal and nondipping pattern correlates with a greater risk of CV and Kidney status is expected to expose chronic kidney disease patients to higher risk, it disease events. 4-6 However, the predictive role of ambuis important to note that each of these alterations per se is latoryBPabovegoalornondippingstatushasbeenalways associated with an increased CV risk (Fig 2). To our evaluated separately by estimating their effect after knowledge, thisfindinghasnotbeenpreviouslydescribed adjustmentforeachother. Becauseinclinicalpracticethese inaCKDpopulation. Thefewstudiesthathaveshownthat 20 AJKD Vol81Iss1January2023 Borrelli et al CVriskisinfluencedbynocturnalnondippingstatusinthe accelerate glomerular filtration rate decline because the transmission of presence of ambulatory blood pressure at goal were performed in higher Hypertension load to the glomerular structure may normotensive participants, patients with treated hyperaccelerate progression of damage in remnant nephrons tension from the general population, 20, 21 or in a small of individuals with chronic kidney disease. 29 group of elderly participants with hypertension. 22 Isolatednondippingstatusposesconcernsregardingthe The mechanisms underlying the increased CV risk in need to increase antihypertensive treatment in patients chronic kidney disease patients with isolated nondipping status are not with ambulatory blood pressure at goal due to the treatment-related readily apparent. Our group previously demonstrated risk of hypoperfusion. However, some therapeutic that nighttime but not daytime blood pressure is a stronger indepenintervention aimed at restoring dipping statussuch as dent predictor of concentric and eccentric LVH. 23 In extracellular volume control, inhibitors of renal artery stenosis, or addition, patients with essential hypertension, showing chronotherapyshould be considered in normotensive nondipping status and ambulatory blood pressure at goal display patients with nondipping status not only because of their higher left ventricular mass index, left atrial volume, and increased cardiorenal risk but also in light of the benefits relative wall thickness. 24, 25 Therefore, we can hypothesize reported by 4 small trials in 872 chronic kidney disease patients in terms of that the higher CV risk observed in our chronic kidney disease patients with CV and renal protection. 30-33 nondipping status may be related to cardiac alterations It is well recognized that disturbances in the circadian induced by the altered circadian rhythm persisting despite rhythm of natriuresis are associated with nondipping ambulatory blood pressure at goal. Unfortunately, we cannot confirm status, particularly in chronic kidney disease patients among whom thishypothesisinourcohortbecauseLVHwascollectedas salt-sensitive hypertension is more frequent. 34-37 Consea dichotomous variable and no data on either left venquently, a Low-salt diet could be more effective in tricular mass or cardiac function were available. restoringthecircadianrhythmofBPasevidencedbysmall Similar to the CV risk findings, having either ambulastudies in essential hypertension and chronic kidney disease. 37, 38 AlternatoryBPabovegoalornondippingstatusexposespatientsto tively, it has been proposed that diuretics could also be agreaterriskoffasterprogressionofkidneydisease(Fig2) effectivebyrestoringthenormalpatternofurinarysodium and Dialysis initiation. This finding is consistent with our excretion. 39, 40 However, this hypothesis has not been previous study reporting that the highest risk of death confirmed by a recent randomized trial in patients with from a Kidney diseaserelated cause is observed in chronic kidney disease advanced chronic kidney disease in which chlorthalidone in comparison patients with nighttime systolic blood pressure above goal and nonwith placebo significantly reduced daytime and nighttime dipping status. 4 In the present study, we extend the blood pressure but to a similar extent and thus not improving the prognostic role of an altered circadian rhythm to those dipping status. 41 In our study, no difference was found patients with ambulatory blood pressure at goal. with respect to diuretic use or implementation of Our results are in contrast with 2 recent retrospective Low-Sodium diet across groups (Table 2).",
    "word_count": 580,
    "char_count": 4429,
    "sentence_count": 22,
    "metadata": {
      "source_file": "1-s2.0-S0272638622007090-main.pdf",
      "extraction_date": "2025-12-31T14:19:31.422573",
      "document_type": "medical_guideline",
      "language": "en",
      "keywords": [
        "chronic kidney disease",
        "CKD",
        "dialysis",
        "nephrology"
      ],
      "chunk_index": 6,
      "total_chunks": 12,
      "position": "7/12",
      "content_type": "evidence",
      "content_type_confidence": 8,
      "medical_entities": [
        "chronic kidney disease",
        "glomerular filtration rate",
        "sodium",
        "diet",
        "diuretics",
        "antihypertensive",
        "dialysis"
      ],
      "entity_count": 7
    }
  },
  {
    "chunk_id": 7,
    "text": "analyses of clinical charts of Omihachiman Community A further strategy to restore normal dipping status is Medical Center in Japan, reporting that nondipping chronotherapy (ie, switching antihypertensive medication status in chronic kidney disease patients with ambulatory blood pressure at goal was from morning to evening). A meta-analysis of studies not associated with Kidney disease events, defined as evaluating bedtime dosing of antihypertensive drugs has estimated glomerular filtration rate decline over 2 years10 or composite end point of shownthatsuchapproachproducesasignificantreduction estimated glomerular filtration rate decline 40%, Kidney failure, or death from kidin nocturnal blood pressure (6. 3/3. 2 mm Hg) with no significant ney diseaserelated cause. 11 Of interest, the Japanese changes in daytime values (1. 7/1. 1 mm Hg) in studies had a larger prevalence of nondipping status comparison with morning administration. 42 We have (83%-86%) than our study and other cohorts of chronic kidney disease previously reported that in chronic kidney disease patients with nondipping patients, 6, 7, 9, 26, 27 including a prospective cohort study status and ambulatory blood pressure at goal chronotherapy was in the same country reporting a prevalence of noneffective in restoring dipping status in 87. 5% of cases and dipping of 53%. 28 Besides the differences in study that this strategy was associated with proteinuria reducdesign and population, the discrepancy with our results tion. 12 These results were not confirmed in a crossover can also be explained based on the use of a different trial performed in Black chronic kidney disease patients, possibly due to a definitionofambulatoryBPatgoal. TheJapanesestudies more pronounced salt-sensitivity blunting the effect of defined ambulatory blood pressure at goal based on 24-hour bedtime dosing. 13 ambulatory blood pressure values (130/80 mm Hg) compared However, before widely implementing therapeutic with our study in which ambulatory blood pressure was classified strategies targeting nondipping status in the presence of atgoalifbothdaytimeandnighttimesystolicBPwere normal ambulatory blood pressure, we should wait for more robust on target. Furthermore, Ida et al11 did not report either evidence from larger ongoing randomized trials, which adjustedrisksofkidneydiseaseoutcomeinthe4groups include more than 13, 500 patients, to definitely prove a or the incidence of each component of the Kidney disreduction of risk of adverse events. 43-45 From a methodease outcome, thus making impossible any direct comological point of view, our findings could be useful for parison. As regards the potential mechanisms, we can highlighting that assessment of dipping status should be hypothesize that the suboptimal control of blood pressure may incorporated into a comprehensive evaluation of blood pressure AJKD Vol81Iss1January2023 21 Borrelli et al control that should not be merely limited to the achieveAdvisory Boards for Astellas. Dr De Nicola has received fees for ment of blood pressure goal. scientific consultation and/or lectures from Astellas, AstraZeneca, Mundibiopharma, andViforPharma. DrMinutolohasbeenmember The primary limitation of this study is inherent to its of Advisory Boards for Amgen, Astellas, Bayer, and GSK, and an observational nature, which forestalls any conclusions invited speaker at meetings supported by Amgen, Astellas, Bayer, regarding cause and effect. Moreover, because all the andViforPharma. Theremainingauthorsdeclarethattheyhaveno participants were White, the data may not be not generrelevantfinancialinterests. alizable to other racial groups who may differ in terms of PeerReview: ReceivedFebruary14, 2022. Evaluatedby2external prevalence of elevated ambulatory blood pressure and dipping stapeerreviewers, withdirecteditorialinputfromaStatistics/Methods tus. 46Inaddition, thisanalysisisbasedononly1instance Editor, an Associate Editor, and the Editor-in-Chief. Accepted in revisedformApril19, 2022. of ambulatory blood pressure monitoring, which may lessen the before mealscuracy of risk stratification; however, in chronic kidney disease patients the diagnosis of abnormal 24-hour blood pressure profile is highly reproducible. 47 References In conclusion, nocturnal nondipping status and ambulatory blood pressure above the goal are distinct predictors of CV and 1.",
    "word_count": 598,
    "char_count": 4390,
    "sentence_count": 26,
    "metadata": {
      "source_file": "1-s2.0-S0272638622007090-main.pdf",
      "extraction_date": "2025-12-31T14:19:31.422573",
      "document_type": "medical_guideline",
      "language": "en",
      "keywords": [
        "chronic kidney disease",
        "CKD",
        "dialysis",
        "nephrology"
      ],
      "chunk_index": 7,
      "total_chunks": 12,
      "position": "8/12",
      "content_type": "evidence",
      "content_type_confidence": 8,
      "medical_entities": [
        "chronic kidney disease",
        "glomerular filtration rate",
        "kidney failure",
        "proteinuria",
        "antihypertensive",
        "monitoring"
      ],
      "entity_count": 6
    }
  },
  {
    "chunk_id": 8,
    "text": "Kidney Disease: Improving Global Outcomes (Kidney Disease: Improving Global Outcomes) Blood PressureWorkGroup. KDIGO2021clinicalpracticeguideline Kidney disease outcomes in chronic kidney disease patients with chronic kidney disease who for the management of Blood Hypertension in chronic Kidney arenot receivingdialysis. Ourresultsconfirmtheessential disease. Kidney Int. 2021; 99(3S): S1-S87. doi: 10. 1016/j. kint. role of ambulatory blood pressure measurement to define accurately 2020. 11. 003 the hypertensive burden and circadian blood pressure profile, thus 2. Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/ allowing better risk stratification in these High-risk AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA patients. guideline for the prevention, detection, evaluation, and management of Hypertension in adults: a report of the American College of Cardiology/American Heart Association Article Information Task Force on Clinical Practice Guidelines. Circulation. AuthorsFullNames andAcademicDegrees: SilvioBorrelli, MD, 2018; 138(17): e484-e594. doi: 10. 1161/CIR. 000000000000 0596 Carlo Garofalo, MD, Francis B. Gabbai, MD, Paolo Chiodini, MSc, Simona Signoriello, MSc, Ernesto Paoletti, MD, Maura Ravera, 3. Williams B, Mancia G, Spiering W, et al. 2018 ESC/ESH MD, Elisabetta Bussalino, MD, Vincenzo Bellizzi, MD, PhD, Maria guidelines for the management of arterial hypertension: the Elena Liberti, MD, Luca De Nicola, MD, PhD, and Roberto TaskForcefortheManagementofArterialHypertensionofthe Minutolo, MD, PhD. European Society ofCardiology and the European Society of Authors Affiliations: Division of Nephrology (SB, CG, MEL, LD, Hypertension published correction appears in J Hypertens. 2019; 37(1): 226. J Hypertens. 2018; 36(10): 1953-2041. doi: RM)andMedicalStatisticsUnit(after meals, SS), UniversityofCampania, Luigi Vanvitelli, Naples, Italy; Department of Medicine, VA San 10. 1097/HJH. 0000000000001940 Diego Healthcare System and University of California at San 4. Minutolo R, Agarwal R, Borrelli S, et al. Prognostic role of Diego Medical School, San Diego, California (fasting blood glucose); Nephrology, ambulatory Blood Hypertension measurement in patients with Dialysis and Transplantation Unit, Policlinico San Martino, Genoa, nondialysis chronic Kidney disease. Arch Intern Med. Italy (EP, MR, EB); and Nephrology Unit, University Hospital San 2011; 171(12): 1090-1098. doi: 10. 1001/archinternmed. 2011. GiovannidiDioeRuggidAragona, Salerno, Italy(VB). 230 Additional Information: This work was endorsed by the Italian 5. AgarwalR, AndersenMJ. Prognosticimportanceofambulatory Society of Nephrology (Gruppo di Studio sul Trattamento Blood Hypertension recordings in patients with chronic Kidney Conservativo della Malattia Renale Cronica) without any financial disease. KidneyInt. 2006; 69(7): 1175-1180. doi: 10. 1038/sj. ki. support. 5000247 6. RahmanM, WangX, BundyJD, etal. Prognosticsignificanceof Address for Correspondence: Roberto Minutolo, MD, PhD, Division of Nephrology, Department of Scienze Mediche e ambulatory blood pressure monitoring in chronic kidney disease: a report from the Chronic Chirurgiche Avanzate, University of Campania Luigi Vanvitelli, Via Renal Insufficiency Cohort (CRIC) Study. J Am Soc Nephrol. M. Longo 50, 80138 Naples, Italy. Email: roberto. minutolo 2020; 31(11): 2609-2621. doi: 10. 1681/American Society of Nephrology. 2020030236 unicampania. it 7. Minutolo R, Gabbai FB, Agarwal R, et al. Assessment of Authors Contributions: Research idea and study design: RM, achievedclinicandambulatorybloodpressurerecordingsand outcomesduringtreatmentinhypertensivepatientswithCKD: fasting blood glucose, LDN; data acquisition: MEL, MR, EP, EB, VB; data analysis/ interpretation: RM, fasting blood glucose, LDN, SB, CG; statistical analysis: after meals, a multicenter prospective cohort study. Am J Kidney Dis. SS, SB, CG; supervision or mentorship: RM, fasting blood glucose, LDN. Each 2014; 64(5): 744-752. doi: 10. 1053/j. ajkd. 2014. 06. 014 authorcontributedimportantintellectual contentduringmanuscript 8. Minutolo R, Gabbai FB, Agarwal R, et al. Sex difference in drafting or revision and agrees to be personally accountable for ambulatory Blood Hypertension control associates with risk of the individuals own contributions and to ensure that questions ESKDanddeathinCKDpatientsreceivingstablenephrology pertaining to the accuracy or integrity of any portion of the work, care. Nephrol Dial Transplant. 2021; 36(11): 2000-2007. doi: even one in which the author was not directly involved, are 10. 1093/ndt/gfab017 appropriately investigated and resolved, including with 9.",
    "word_count": 594,
    "char_count": 4649,
    "sentence_count": 67,
    "metadata": {
      "source_file": "1-s2.0-S0272638622007090-main.pdf",
      "extraction_date": "2025-12-31T14:19:31.422573",
      "document_type": "medical_guideline",
      "language": "en",
      "keywords": [
        "chronic kidney disease",
        "CKD",
        "dialysis",
        "nephrology"
      ],
      "chunk_index": 8,
      "total_chunks": 12,
      "position": "9/12",
      "section": "Kidney Disease:",
      "content_type": "evidence",
      "content_type_confidence": 4,
      "medical_entities": [
        "chronic kidney disease",
        "dialysis",
        "monitoring",
        "guideline"
      ],
      "entity_count": 4
    }
  },
  {
    "chunk_id": 9,
    "text": "1093/ndt/gfab017 appropriately investigated and resolved, including with 9. Gabbai FB, Rahman M, Hu B, et al. Relationship between documentationintheliteratureifappropriate. ambulatory blood pressure and clinical outcomes in patients with Support: None. hypertensive chronic kidney disease. Clin J Am Soc Nephrol. 2012; 7(11): FinancialDisclosure: DrPaolettihasreceivedconsultantfeesfrom 1770-1776. doi: 10. 2215/CJN. 11301111 Bayer, Vifor Fresenius, and Novartis, and lecture fees from 10. Kado H, Kusaba T, Matoba S, Hatta T, Tamagaki potassium. NormoAstraZeneca and Vifor Pharma. Dr Ravera has been a member of tensivenon-dippingbloodpressureprofiledoesnotpredictthe 22 AJKD Vol81Iss1January2023 Borrelli et al risk of chronic Kidney disease progression. Hypertens Res. 25. Mezue potassium, Isiguzo G, Madu C, et al. Nocturnal non-dipping 2019; 42(3): 354-361. doi: 10. 1038/s41440-018-0155-9 Blood Hypertension profile in Black normotensives is associated 11. Ida T, Kusaba T, Kado H, et al. Ambulatory Blood Hypertension with cardiac target organ damage. Ethn Dis. 2016; 26(3): monitoring-based analysis of long-term outcomes for Kidney 279-284. doi: 10. 18865/ed. 26. 3. 279 diseaseprogression. SciRep. 2019; 9(1): 19296. doi: 10. 1038/ 26. Sarafidis PA, Ruilope LM, Loutradis C, et al. Blood Hypertension s41598-019-55732-4 variability increases with advancing chronic Kidney disease 12. MinutoloR, GabbaiFB, BorrelliS, etal. Changingthetimingof stage: a cross-sectional analysis of 16546 hypertensive paantihypertensivetherapytoreducenocturnalbloodpressurein tients. JHypertens. 2018; 36(5): 1076-1085. doi: 10. 1097/HJH. chronic kidney disease: an 8-week uncontrolled trial. Am J Kidney Dis. 0000000000001670 2007; 50(6): 908-917. doi: 10. 1053/j. ajkd. 2007. 07. 020 27. DrawzPE, AlperAB, AndersonAH, etal. Maskedhypertension 13. RahmanM, GreeneT, PhillipsRA, etal. Atrialof2strategiesto andelevatednighttimebloodpressureinCKD: prevalenceand reducenocturnalbloodpressureinblackswithchronickidney associationwithtargetorgandamage. ClinJAmSocNephrol. disease. Hypertension. 2013; 61(1): 82-88. doi: 10. 1161/ 2016; 11(4): 642-652. doi: 10. 2215/CJN. 08530815 HYPERTENSIONAHA. 112. 200477 28. IimuroS, ImaiE, WatanabeT, et al. Clinicalcorrelatesofambu14. ESH/ESC Task Force for the Management of Arterial HyperlatoryBPmonitoringamongpatientswithCKD. ClinJAmSoc tension. 2013 Practice guidelines for the management of Nephrol. 2013; 8(5): 721-730. doi: 10. 2215/CJN. 06470612 arterialhypertensionoftheEuropeanSocietyofHypertension 29. Brenner BM, Lawler EV, Mackenzie at bedtime. The hyperfiltration (ESH) and the European Society of Cardiology (ESC): ESH/ theory: aparadigmshiftinnephrology. KidneyInt. 1996; 49(6): ESCTask Force for the management of arterial hypertension. 1774-1777. doi: 10. 1038/ki. 1996. 265 J Hypertens. 2013; 31(10): 1925-1938. doi: 10. 1097/HJH. 30. Hermida RC, Ayala DE, Mojo(cid: 1)n A, Fern(cid: 1)andez JR. Bedtime 0b013e328364ca4c dosingofantihypertensivemedicationsreducescardiovascular 15. SkaliH, UnoH, LeveyAS, InkerLA, PfefferMA, SolomonSD. riskinCKD. JAmSocNephrol. 2011; 22(12): 2313-2321. doi: Prognostic assessment of estimated glomerular estimated glomerular filtration rate 10. 1681/American Society of Nephrology. 2011040361 by the new Chronic Kidney Disease Epidemiology Collabora31. Tiwari V, Chaudhary AR, Dasgupta S, et al. Effect of tion equation in comparison with the Modification of Diet in chronotherapyofantihypertensivesinchronickidneydisease: a Renal Disease Study equation. Am Heart J. 2011; 162(3): randomized control trial. Indian J Nephrol. 2021; 31(1): 9-15. 548-554. doi: 10. 1016/j. ahj. 2011. 06. 006 doi: 10. 4103/ijn. IJN_322_19 16. Schemper M, Smith TL. A note on quantifying follow-up in 32. WangC, ZhangJ, LiuX, etal. Effectofvalsartanwithbedtime studies of failure time. Control Clin Trials. 1996; 17(4): dosing on chronic Kidney disease patients with nondipping 343-346. doi: 10. 1016/0197-2456(96)00075-x Blood Hypertension pattern. J Clin Hypertens (Greenwich). 17. Fine JP, Gray RJ. A proportional hazards model for the 2013; 15(1): 48-54. doi: 10. 1111/jch. 12021 subdistribution of a competing risk. J Am Stat Assoc. 33. YanagiM, TamuraK, FujikawaT, etal. TheangiotensinIItype1 1999; 94(446): 496-509. doi: 10. 1080/01621459. 1999. receptor blocker olmesartan preferentially improves nocturnal 10474144 hypertension and proteinuria in chronic Kidney disease. 18. Gray RJ. A class of potassium-sample tests for comparing the cumuHypertens Res. 2013; 36(3): 262-269. doi: 10. 1038/heart rate. 2012. lative incidence of a competing risk. Ann Stat. 1988; 16: 184 1141-1154. 34. Kimura G, Dohi Y, Fukuda M. Salt sensitivity and circadian 19. Minutolo R, Borrelli S, Chiodini P, et al.",
    "word_count": 594,
    "char_count": 4760,
    "sentence_count": 126,
    "metadata": {
      "source_file": "1-s2.0-S0272638622007090-main.pdf",
      "extraction_date": "2025-12-31T14:19:31.422573",
      "document_type": "medical_guideline",
      "language": "en",
      "keywords": [
        "chronic kidney disease",
        "CKD",
        "dialysis",
        "nephrology"
      ],
      "chunk_index": 9,
      "total_chunks": 12,
      "position": "10/12",
      "content_type": "evidence",
      "content_type_confidence": 3,
      "medical_entities": [
        "chronic kidney disease",
        "glomerular filtration rate",
        "proteinuria",
        "potassium",
        "diet",
        "monitoring"
      ],
      "entity_count": 6
    }
  },
  {
    "chunk_id": 10,
    "text": "34. Kimura G, Dohi Y, Fukuda M. Salt sensitivity and circadian 19. Minutolo R, Borrelli S, Chiodini P, et al. Effects of age on rhythm of Blood Hypertension: the keys to connect chronic kidney disease with hypertensive status in patients with chronic Kidney disease. cardiovascular events. Hypertens Res. 2010; 33(6): 515-520. J Hypertens. 2007; 25(11): 2325-2333. doi: 10. 1097/HJH. doi: 10. 1038/heart rate. 2010. 47 0b013e3282ef549e 35. Fukuda M, Munemura M, Usami T, et al. Nocturnal Blood 20. HermidaRC, AyalaDE, Mojo(cid: 1)sodium, Fern(cid: 1)andezJR. BluntedsleepHypertension is elevated with natriuresis and proteinuria as renal time relative Blood Hypertension decline increases cardiovascular function deteriorates in nephropathy. Kidney Int. 2004; 65(2): risk independent of Blood Hypertension levelthe normotensive 621-625. doi: 10. 1111/j. 1523-1755. 2004. 00419. x non-dipperparadox. ChronobiolInt. 2013; 30(1-2): 87-98. doi: 36. FukudaM, KimuraG. Saltsensitivityandnondippersinchronic 10. 3109/07420528. 2012. 701127 kidneydisease. CurrHypertensRep. 2012; 14(5): 382-387. doi: 21. Ohkubo T, Hozawa A, Yamaguchi J, et al. Prognostic signifi10. 1007/s11906-012-0286-3 canceofthenocturnaldeclineinbloodpressureinindividuals 37. FujiiT, UzuT, NishimuraM, etal. Circadianrhythmofnatriuresis withandwithouthigh24-hbloodpressure: theOhasamastudy. isdisturbedinnondippertypeofessentialhypertension. AmJ J Hypertens. 2002; 20(11): 2183-2189. doi: 10. 1097/ Kidney Dis. 1999; 33(1): 29-35. doi: 10. 1016/s0272-6386(99) 00004872-200211000-00017 70254-4 22. Pierdomenico SD, Pierdomenico AM, Coccina F, Lapenna D, 38. Uzu T, Ishikawa potassium, Fujii T, Nakamura S, Inenaga T, Kimura G. PorrecaE. Prognosticvalueofnondippingandmorningsurge Sodium restriction shifts circadian rhythm of Blood Hypertension in elderly treated hypertensive patients with controlled fromnondippertodipperinessentialhypertension. Circulation. ambulatory Blood Hypertension. Am J Hypertens. 2017; 30(2): 1997; 96(6): 1859-1862. doi: 10. 1161/01. cir. 96. 6. 1859 159-165. doi: 10. 1093/ajh/hpw145 39. Uzu T, Kimura G. Diuretics shift circadian rhythm of Blood 23. Paoletti E, De Nicola L, Gabbai FB, et al. Associations of left Hypertension from nondipper to dipper in essential hypertension. ventricularhypertrophyandgeometrywithadverseoutcomesin Circulation. 1999; 100(15): 1635-1638. doi: 10. 1161/01. cir. patientswithCKDandhypertension. ClinJAmSocNephrol. 100. 15. 1635 2016; 11(2): 271-279. doi: 10. 2215/CJN. 06980615 40. Fuwa D, Fukuda M, Ogiyama Y, et al. Addition of hydrochlo24. Hoshide S, Kario potassium, Hoshide Y, et al. Associations between rothiazidetoangiotensinreceptorblockertherapycanachieve nondipping of nocturnal Blood Hypertension decrease and alowersodiumbalancewithnoaccelerationofintrarenalrenin cardiovascular target organ damage in strictly selected angiotensin system in patients with chronic Kidney disease. community-dwelling normotensives. Am J Hypertens. J Renin Angiotensin Aldosterone Syst. 2016; 17(2): 2003; 16(6): 434-438. doi: 10. 1016/s0895-7061(03)00567-3 1470320316652032. doi: 10. 1177/1470320316652032 AJKD Vol81Iss1January2023 23 Borrelli et al 41. Agarwal R, Sinha AD, Cramer AE, et al. Chlorthalidone for 45. Rorie DA, Rogers A, Mackenzie IS, et al. Methods of a large hypertensioninadvancedchronickidneydisease. NEnglJMed. prospective, randomised, open-label, blinded end-point study 2021; 385(27): 2507-2519. doi: 10. 1056/NEJMoa2110730 comparing morning versus evening dosing in hypertensive 42. Sun Y, Yu X, Liu J, et al. Effect of bedtime administration of patients: the Treatment In Morning versus Evening (TIME) Blood-pressureloweringagentsonambulatorybloodpressure study. BMJOpen. 2016; 6(2): e010313. doi: 10. 1136/bmjopenmonitoring results: a meta-analysis. Cardiol J. 2016; 23(4): 2015-010313 473-481. doi: 10. 5603/CJ. a2016. 0027 46. DrawzPE, BrownR, DeNicolaL, etal. Variationsin24-hourBP 43. Georgianos PI, Agarwal R. Can we mendthe broken clock by profiles in cohorts of patients with Kidney disease around the timingantihypertensivetherapysensibly? ClinJAmSocNephworld: theI-DAREstudy. ClinJAmSocNephrol. 2018; 13(9): rol. 2020; 15(10): 1513-1515. doi: 10. 2215/CJN. 00360120 1348-1357. doi: 10. 2215/CJN. 13181117 44. Garrison SR, Kolber MR, Allan GM, et al. Bedtime versus 47. Minutolo R, Gabbai FB, Chiodini P, et al. Reassessment of morning use of antihypertensives for cardiovascular risk ambulatory Blood Hypertension improves renal risk stratification in reduction (BedMed): protocol for a prospective, randomised, nondialysis chronic Kidney disease: long-term cohort study. open-label, blinded end-point pragmatic trial. BMJ Open. Hypertension. 2015; 66(3): 557-562. doi: 10. 1161/HYPER2022; 12(2): e059711. doi: 10. 1136/bmjopen-2021-059711 TENSIONAHA. 115.",
    "word_count": 582,
    "char_count": 4813,
    "sentence_count": 122,
    "metadata": {
      "source_file": "1-s2.0-S0272638622007090-main.pdf",
      "extraction_date": "2025-12-31T14:19:31.422573",
      "document_type": "medical_guideline",
      "language": "en",
      "keywords": [
        "chronic kidney disease",
        "CKD",
        "dialysis",
        "nephrology"
      ],
      "chunk_index": 10,
      "total_chunks": 12,
      "position": "11/12",
      "section": "34. Kimura G",
      "content_type": "evidence",
      "content_type_confidence": 5,
      "medical_entities": [
        "chronic kidney disease",
        "nephropathy",
        "proteinuria",
        "sodium",
        "potassium",
        "sodium restriction",
        "diuretics"
      ],
      "entity_count": 7
    }
  },
  {
    "chunk_id": 11,
    "text": "BMJ Open. Hypertension. 2015; 66(3): 557-562. doi: 10. 1161/HYPER2022; 12(2): e059711. doi: 10. 1136/bmjopen-2021-059711 TENSIONAHA. 115. 05820 24 AJKD Vol81Iss1January2023 Borrelli et al Dipping Status, Ambulatory Blood Hypertension Control, cardiovascular disease, and Kidney Disease Progression Setting Participants Groups Outcomes Results Multicenter cohort N (%) ABP at Goal Dipping study Adjusted Risk Group 1 167 (18) Yes Yes heart rate (95%CI) 3 nephrology clinics Group 2 187 (21) Yes No in Italy CV Outcome end-stage kidney disease Group 3 103 (11) No Yes Group 1 Reference Reference N 906 ND-chronic kidney disease Group 4 449 (50) No No patients 2. 06 1. 82 Group 2 CCV outcome (1. 15-3. 68) (1. 17-2. 82) Systolic ABP at goal Composite of non-fatal CV events 2. 05 2. 11 Daytime 135 mmHg Group 3 Nighttime 120 mmHg rrequiring hospitalization or CV death (1. 10-3. 84) (1. 28-3. 48) Dipping EESKD Group 4 2. 79 2. 40 Night/day ratio of CComposite of estimated glomerular filtration rate decline 50% (1. 64-4. 75) (1. 58-3. 65) systolic blood pressure 0. 9 oor KRT CONCLUSION: The presence of either ABP above goal or non-dipping status (even if ABP was at goal) was CON associated with higher risks of cardiovascular disease and Kidney disease progression in chronic kidney disease patients. Silvio Borrelli, Carlo Garofalo, Francis B. Gabbai, et al AJKDonline DOI: 10. 1053/j. ajkd. 2022. 04. 010 AJKD Vol81Iss1January2023 24. e1",
    "word_count": 232,
    "char_count": 1442,
    "sentence_count": 33,
    "metadata": {
      "source_file": "1-s2.0-S0272638622007090-main.pdf",
      "extraction_date": "2025-12-31T14:19:31.422573",
      "document_type": "medical_guideline",
      "language": "en",
      "keywords": [
        "chronic kidney disease",
        "CKD",
        "dialysis",
        "nephrology"
      ],
      "chunk_index": 11,
      "total_chunks": 12,
      "position": "12/12",
      "content_type": "evidence",
      "content_type_confidence": 3,
      "medical_entities": [
        "chronic kidney disease",
        "glomerular filtration rate",
        "cardiovascular disease"
      ],
      "entity_count": 3
    }
  }
]